Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis

Jung, Richard G.; Motazedian, Pouya; Ramirez, F. Daniel; Simard, Trevor; Santo, Pietro Di; Visintini, Sarah; Faraz, Mohammad Ali; Labinaz, Alisha; Jung, Young; Hibbert, Benjamin

doi:10.1186/s12959-018-0166-4

Cited by 100 publications

(81 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Research of Tani et al (2015) in DM2 patients indicated significant decreased PAI-1 level, serum TGL, and Apo B concentration after vildagliptin treatment [29]. A systemic review of 38 articles evaluating PAI-1 levels in 11,557 patients revealed that elevated plasma PAI-1 antigen levels are associated with higher risk of death, myocardial infarction, or cerebrovascular accident [108].…”

Section: Lipids Metabolism Disordersmentioning

confidence: 99%

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Wiciński

Górski

Wódkiewicz

et al. 2020

IJMS

View full text Add to dashboard Cite

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitors polypeptide) and prolong their action. Some studies present results suggesting the anti-sclerotic and vasculoprotective effects of vildagliptin reaching beyond glycemic control. Vildagliptin is able to limit inflammation by suppression of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway and proinflammatory agents such as TNF-α (tumor necrosis factor α), IL-1β (Interleukin-1β), and IL-8 (Interleukin 8). Moreover, vildagliptin regulates lipid metabolism; attenuates postprandial hypertriglyceridemia; and lowers serum triglycerides, apolipoprotein B, and blood total cholesterol levels. This DPP-4 inhibitor also reduces macrophage foam cell formation, which plays a key role in atheromatous plaque formation and stability. Vildagliptin reduces vascular stiffness via elevation of nitric oxide synthesis, improves vascular relaxation, and results in reduction in both systolic and diastolic blood pressure. Treatment with vildagliptin lowers the level of PAI-1 presenting possible antithrombotic effect. By affecting the endothelium, inflammation, and lipid metabolism, vildagliptin may affect the development of atherosclerosis at its various stages. The article presents a summary of the studies assessing vasculoprotective effects of vildagliptin with special emphasis on atherogenesis.

show abstract

Section: Lipids Metabolism Disordersmentioning

confidence: 99%

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Wiciński

Górski

Wódkiewicz

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Chemerin, is a chemoattractant protein, that is necessary for adipogenesis, which when elevated in adipose tissue may be a marker for the onset of DM [17]. Visfatin is an enzyme that activates insulin and has insulin-mimetic effects [18], whereas plasminogen activator inhibitor-1 (PAI-1), is the primary inhibitor of tissue-and urokinase-type plasminogen activators, and considered to be a critical regulator of the fibrinolytic system [19]. Finally, resistin promotes hepatic production of low density lipoproteins (LDL), which degrades LDL receptors [20].…”

Section: Introductionmentioning

confidence: 99%

Effect of Bariatric Surgery on the Circulating Level of Adiponectin, Chemerin, Plasminogen Activator Inhibitor-1, Leptin, Resistin, and Visfatin: A Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Different adipokines secreted from adipose tissue, exert a range of physiological effects. The aim of present systematic review and meta-analysis was to critically investigate the consequence of bariatric surgery on circulating adipokines, that is, adiponectin, leptin, visfatin, resistin, plasminogen activator inhibitor, and chemerin. After systematically checking the following electronic databases: ISI web of Science, Scopus and PubMed without limitation in time and language up to February 2019, a pool based on a random effect model was established. Eighty-five eligible studies were entered for quantitative analysis. Our meta-analysis revealed that circulating adiponectin increased significantly after bariatric surgery [Standardized mean difference (SMD)=1.401, 95% CI: 1.101, 1.701, p<0.001]; whilst leptin (SMD=–2.178, 95% CI: –2.433, –1.923, p<0.001), PAI-1 (–14.928 ng/ml 95% CI: –21.794, –8.063, p<0.001), and chemerin (–50.238 ng/ml 95% CI: –85.708, –14.768, p<0.001) decreased. However, serum visfatin (2.05 ng/ml, 95% CI: –5.07, 9.17, p=0.573) and resistin (–2.080 ng/ml, 95% CI: –5.352, 1.192, p=0.21) were unchanged. In conclusion, bariatric surgery is associated with a reduction in specific adipokines including leptin, chemerin, and PAI-1, whereas adiponectin is raised, adaptations that could be indicative of improved fat mass and function.

show abstract

“…Stress has a great impact on neurodegenerative diseases, having a great role in its development, progress and evolution [180]. [188].…”

Section: Metabolic Diseases and Their Affinity For Alzheimer's Diseasementioning

confidence: 99%

The Physiopathological Crossroads of Aging

J¹,

Coronel²,

Pascual-Salcedo³

et al. 2019

JBM

View full text Add to dashboard Cite

Stress, inflammation and Plasminogen activator inhibitor 1 (PAI-1) are key mechanisms throughout the development of aging, constituting a crossroad in the most frequent pathologies that accompany it. Among metabolic processes, obesity, metabolic syndrome and type 2 diabetes mellitus are included and Alzheimer's disease among the neurodegenerative processes. Stress is a mechanism of defense of the organism against exogenous and endogenous actions called stressors. In the case of low intensity stimuli, the organism responds with actions aimed at a physiological adaptation (Homeostasis). On the other hand, when a high intensity (experimental level) or chronic stimulus (oxidative stress) is repeated, structural and functional changes are observed in different organs with activation of the hypothalamus-pituitary-adrenal axis, the renin angiotensin system and the sympathetic nervous system, stimulating the production of hormones that release cytokines with proinflammatory/antiinflammatory properties that play an important role in the previously mentioned pathologies, as well as a marked increase in PAI-1, a gene regulated by stress and by cytokines, with manifest action at the origin of thromboembolic disease, so frequent in aging. The objective of this review is to highlight the importance of the binomial stress and PAI-1 in aging and in the pathologies that accompany it. Because PAI-1 is part of the pathology and complications in aging, some authors suggest the study of PAI-1 inhibitors to achieve its physiological levels, as part of the treatment of these diseases.

show abstract

Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis

Cited by 100 publications

References 78 publications

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Effect of Bariatric Surgery on the Circulating Level of Adiponectin, Chemerin, Plasminogen Activator Inhibitor-1, Leptin, Resistin, and Visfatin: A Systematic Review and Meta-Analysis

The Physiopathological Crossroads of Aging

Contact Info

Product

Resources

About